Refractive trend worth watching with Dr. Elise Kramer

Refractive trend worth watching with Dr. Elise Kramer We’re seeing a meaningful increase in corneal cross-linking for #keratoconus and the data explains why. With the FDA approval of epithelium-on cross-linking Epioxa (Epioxa HD/Epioxa), treatment is now less invasive while still doing what matters most: halting disease progression. That stability can delay, or even prevent the need for corneal transplants and other invasive procedures. What’s especially notable? Progression isn’t limited to younger patients. Nearly 44% of patients over 35 can still progress, challenging what many of us were taught years ago. For keratoconus specialists and contact lens fitters, this shift means earlier intervention, longer stability, and better long-term outcomes for patients. A real evolution in how we manage keratoconus. #IDSocial #Keratoconus #CrossLinking #RefractiveTrends #Ophthalmology #Optometry #CorneaCare Financial Disclosures: none acknowledged